BrainsWay Ltd. (NASDAQ:BWAY – Free Report) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of BrainsWay in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.18 for the year, down from their prior estimate of $0.32. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.
BrainsWay Price Performance
Shares of NASDAQ BWAY opened at $10.21 on Monday. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. BrainsWay has a one year low of $4.61 and a one year high of $11.79. The firm’s 50 day simple moving average is $10.26 and its two-hundred day simple moving average is $9.63.
Hedge Funds Weigh In On BrainsWay
BrainsWay Company Profile
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Recommended Stories
- Five stocks we like better than BrainsWay
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- How to Build the Ultimate Everything ETF Portfolio
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.